Form 4: Organon Executive Daniel Karp Reports Stock Transactions

Executive VP Daniel Karp acquired shares through RSU vesting and disposed of shares to cover tax obligations.

Summary

• Daniel Karp, Executive VP of Corporate Development at Organon & Co., reported the vesting of Restricted Stock Units (RSUs) and subsequent share sales.
• A total of 18,053 shares were acquired through the vesting of RSUs on March 31, 2026.
• A total of 5,659 shares were withheld by the company to satisfy tax withholding obligations at a price of $5.70 per share.
• The reporting person was granted a new award of 100,166 RSUs on March 31, 2026, which will vest in three equal annual installments starting March 31, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine executive equity compensation and tax-related share withholding.

Positives

• The executive continues to hold a significant stake in the company, with 69,547.923 shares beneficially owned following the transactions.
• The grant of 100,166 new RSUs aligns the executive's long-term interests with shareholder value through a three-year vesting schedule.

Negatives

• The disposal of 5,659 shares was necessary to cover tax liabilities associated with the vesting of equity awards.

Risks

• The value of the equity holdings is subject to market volatility, as evidenced by the $5.70 per share valuation used for tax withholding.

Future Outlook

The executive received a new grant of 100,166 RSUs that will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029, indicating a continued long-term commitment to the company.

Industry Context

StockSavvy.ai notes that this filing represents standard executive compensation activity within the pharmaceutical sector, where equity-based incentives are common to retain key leadership talent.

Comparison to Industry Standards

• The use of RSUs as a primary component of executive compensation is consistent with standard practices at large-cap pharmaceutical companies like Pfizer or Merck.
• The three-year vesting schedule for new grants is standard for executive retention programs in the industry.

Stakeholder Impact

• Shareholders should note the continued alignment of executive interests through long-term equity vesting.

Next Steps

• Vesting of the first installment of the new 100,166 RSU grant on March 31, 2027.

Key Dates

Keywords

Organon, OGN, Form 4, Insider Trading, Restricted Stock Units, Executive Compensation